FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Cancer
- Advanced Solid Tumors
- EGFR Positive Solid Tumor
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- HER2 Positive Gastric Cancer
- HER2 Positive Breast Cancer
- Melanoma
- Non -Small Cell Lung Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03319459
- Collaborators
- Not Provided
- Investigators
- Study Director: Sarah Cooley, MD Fate Therapeutics